This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Downbeat 2018? These 5 Top Stocks Are Up More Than 100%
by Sanghamitra Saha
These five stocks gained more than 100% defying the market sluggishness this year.
Zacks.com highlights: Baytex Energy, Capstone Turbine, Endocyte, First BanCorp and FuelCell
by Zacks Equity Research
Zacks.com highlights: Baytex Energy, Capstone Turbine, Endocyte, First BanCorp and FuelCell
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include BTE, CPST, ECYT, FBP and FCEL.
Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll
by Zacks Equity Research
Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll
New Analyst Coverage Puts Spotlight on 5 Stocks
by Zacks Equity Research
More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Endocyte (ECYT) Catches Eye: Stock Jumps 7.7%
by Zacks Equity Research
Endocyte (ECYT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
Endocyte (ECYT) Posts Wider than Expected Loss in Q4
by Zacks Equity Research
Endocyte???s fourth-quarter 2017 loss was wider-than-expected.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock
by Zacks Equity Research
Investors in Endocyte (ECYT) need to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock
by Zacks Equity Research
Surging implied volatility makes Endocyte (ECYT) stock lucrative to the option traders.
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss
by Zacks Equity Research
Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.
Will Endocyte (ECYT) Disappoint This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.
Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up
by Zacks Equity Research
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock
by Zacks Equity Research
Endocyte (ECYT) needs Investors to pay close attention to the stock based on moves in the options market lately.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
by Zacks Equity Research
Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.
What's in Store for Endocyte (ECYT) this Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) is slated to release third-quarter fiscal 2017 results before the market opens on Jun 29.
Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report?
by Zacks Equity Research
Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
by Zacks Equity Research
Endocyte reported a loss per share of 27 cents per share while our consensus called for a loss of 28 cents per share.